Findings from a five-year trial of 5% imiquimod cream for treating superficial and nodular basal cell carcinomas show sustained benefits for those lesions that respond to the cream early, though surgery remains a superior intervention, according to a paper published online ahead of print in Journal of Investigative Dermatology (Dec. 5, 2016). This research was an extension of an earlier three-year follow-up study comparing 5% imiquimod cream to traditional Mohs excision, whic